查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
抗体药物复合体(ADC) 的全球市场 (~2028)：依产品类型、接头类型、有效负载类型、标靶、疾病和区域
市场调查报告书
商品编码
1366407

抗体药物复合体(ADC) 的全球市场 (~2028)：依产品类型、接头类型、有效负载类型、标靶、疾病和区域

Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 273 Pages | 订单完成后即时交付

价格
简介目录

全球抗体药物复合体(ADC) 市场规模预计将从 2023 年的 97 亿美元成长到 2028 年的 198 亿美元，预测期内年复合成长率为 15.2%。

癌症患病患病上升、正在进行临床研究的稳健产品以及不断增加的行业合作等要素预测将推动市场的成长。

调查范围
调查年份 2021-2028
基准年 2022年
预测期 2023-2028
单元 金额（美元）
按部门 依产品类型、疾病类型、接头类型、标靶和有效负载类型
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

Kadcyla 的部门在抗体药物复合体(ADC) 市场占据压倒性份额

按按产品，Kadcyla部门到 2022 年将占据最大份额。 Kadcyla 广泛用于乳癌治疗，预计将推动市场成长。此外，Polivy 和 Adcertis 最近获得的各种适应症的核准也可能在未来几年进一步提振市场。

按疾病类型划分，2022年乳癌部门将占最大份额

依疾病类型划分，乳癌部门所占比重最大。由于多种要素，包括乳癌患病的增加以及乳癌 ADC 的需求不断增长，该部门占据了市场份额。生物相似药的推出预测也将对市场成长产生进一步的正面影响。

亚太地区预测将以更快的速度成长

按地区划分，预计亚太地区在预测期内将以更高的年复合成长率成长。中国和日本政府对 ADC 的核准不断增加，以及用于乳癌治疗的生物相似药 Ujvira 在印度的推出，预计将推动该地区的市场成长。

本报告调查了全球抗体药物复合体（ADC）市场，并提供了市场概况、市场影响因素和市场机会分析、技术和专利趋势、法律制度、市场规模趋势和预测、各种分类和详细总结。区域分析、竞争形势和主要企业概况。

目录

第1章简介

第2章调查方法

第3章执行摘要

第4章重要考察

第5章市场概况

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 管道分析
  • 价值链分析
  • 生态系分析
  • 技术分析
  • 法规评估
  • 波特五力分析
  • 专利分析
  • 影响客户业务的趋势/干扰
  • 价格分析
  • 重大会议及活动
  • 主要利害关係人和采购标准

第6章抗体药物复合体（ADC）市场：按产品

  • KADCYLA
  • ENHERTU
  • ADCETRIS
  • PADCEV
  • TRODELVY
  • POLIVY
  • 其他的

第7章抗体药物复合体（ADC）市场：依连接子类型

  • 可切割连接器
  • 不可切割的接头

第8章抗体药物复合体（ADC）市场：依目标类型

  • HER2
  • CD22
  • CD30
  • 其他的

第9章抗体药物复合体（ADC）市场：按有效负载类型

  • 单甲基阿里他汀E
  • 加利车霉素
  • 美登木素生物碱
  • 其他的

第10章抗体药物复合体（ADC）市场：依疾病类型

  • 乳癌
  • 血癌
  • 其他的

第11章抗体药物复合体（ADC）市场：按地区

  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第12章竞争形势

  • 主要企业的招募策略
  • 收益占有率分析
  • 市场占有率分析
  • 主要企业企业评价矩阵
  • 竞争基准化分析
  • 新创公司/中小企业的企业评估矩阵
  • 新创公司/中小企业的竞争基准化分析
  • 竞争场景/趋势

第13章公司简介

  • 主要企业
    • F. HOFFMANN-LA ROCHE LTD.
    • DAIICHI SANKYO COMPANY, LIMITED
    • SEAGEN INC.
    • GILEAD SCIENCES, INC.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • PFIZER INC.
    • ASTELLAS PHARMA INC.
    • ASTRAZENECA
    • ADC THERAPEUTICS SA
    • IMMUNOGEN, INC.
    • ZYDUS GROUP
  • 其他公司
    • ABBVIE INC.
    • AMBRX
    • LEGOCHEM BIOSCIENCES, INC.
    • BYONDIS
    • PROFOUNDBIO
    • REMEGEN
    • SUTRO BIOPHARMA, INC.
    • LEPU BIOPHARMA CO., LTD.
    • ZYMEWORKS INC.
    • MERSANA THERAPEUTICS
    • DUALITY BIOLOGICS
    • LANOVA MEDICINES
    • EXELIXIS, INC.
    • BIONECURE THERAPEUTICS INC.
    • TRIPARTITE THERAPEUTICS, INC.

第14章附录

简介目录
Product Code: BT 8808

The global antibody drug conjugates market size is projected to reach USD 19.8 billion by 2028 from USD 9.7 billion in 2023, at a CAGR of 15.2% during the forecast period. Factors such as the rising prevalence of cancer, robust products under clinical studies, and increased industrial collaborations are likely to drive market growth. For instance, in August 2023, ImmunoGen, Inc. entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan.

Scope of the Report
Years Considered for the Study 2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) billion
SegmentsBy Product, By Disease Type, By Linker type, By Target, By Payload Type
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

"The Kadcyla segment held the dominant share in the antibody drug conjugates market."

Based on product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and others. The Kadcyla segment accounted for the largest share of the market in 2022. Extensive use of Kadcyla for breast cancer treatment is likely to drive the growth of

the market. Recent approvals for various disease indications for Polivy and Adcertis are further likely to uplift the market in the coming years.

"Breast cancer segment accounted for the largest share of the disease type segment in 2022."

Based on disease type, the antibody drug conjugates market is segmented into breast cancer, lung cancer and other diseases. In 2022, the breast cancer segment accounted for the largest share of the antibody drug conjugates market. The segment held the dominant share in the market owing to various factors such as the increasing prevalence of breast cancer coupled with the rising demand for ADCs for breast cancer. The launch of biosimilar is further likely to have a positive impact on the market growth.

"Asia Pacific region is likely to grow at a faster pace."

The antibody-drug conjugates market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. Rising approvals from the government for ADCs in China and Japan. The launch of the biosimilar Ujvira for the treatment of breast cancer in India is likely to give momentum to the market growth in the region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%, and Demand Side - 20%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

List of Companies Profiled in the Report:

  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Daiichi Sankyo Company, Limited (Japan)
  • Seagen Inc. (US)
  • Gilead Sciences, Inc. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Pfizer Inc. (US),
  • Astellas Pharma Inc (Japan)
  • AstraZeneca (UK)
  • ADC Therapeutics SA (Switzerland)
  • ImmunoGen, Inc. (US)
  • Zydus Group (India)
  • Abbvie Inc. (US)
  • Ambrx (US)
  • LegoChem Biosciences, Inc. (South Korea)
  • Byondis (Netherlands)
  • ProfoundBio (China)
  • RemeGen (China)
  • Sutro Biopharma, Inc. (US)
  • Lepu Biopharma CO., Ltd. (China)
  • Zymeworks Inc. (Canada)
  • Mersana Therapeutics (US)
  • Duality Biologics (China)
  • LaNova Medicines (China)
  • Exelixis, Inc. (US)
  • BiOneCure Therapeutics Inc. (US)
  • Tripartite Therapeutics, Inc. (Taiwan).

Research Coverage:

This report provides a detailed picture of the antibody drug conjugates market. It aims to estimate the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall antibody drug conjugates market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising incidence of cancer, Increased investment and collaborations by key market players for the development of novel ADCs, Growing number of ADCs in clinical trials, Regulatory support for ADC development ), restraints ( High manufacturing costs, Side effects associated with ADCs, High attrition rate in product development), opportunities (Adoption of combination therapies, High growth in emerging economies, Emergence of advanced ADCs) and challenges (Technical complexities) are influencing the growth of antibody drug conjugates market.
  • Product Development/Innovation: Detailed insights on newly launched products of the antibody drug conjugates market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the antibody drug conjugates market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the antibody drug conjugates market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), Zydus Group (India) and among others in the antibody drug conjugates market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 RESEARCH LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 ANTIBODY DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 ANTIBODY DRUG CONJUGATES MARKET: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS (2022)
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)
    • FIGURE 5 ANTIBODY DRUG CONJUGATES MARKET: REVENUE SHARE ANALYSIS OF F-HOFFMAN LA ROCHE LTD.
    • 2.2.1 PRIMARY INSIGHTS
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT METHODOLOGY
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH RATE ASSUMPTIONS
    • FIGURE 8 ANTIBODY DRUG CONJUGATES MARKET: CAGR PROJECTION ANALYSIS
    • FIGURE 9 ANTIBODY DRUG CONJUGATES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF ANTIBODY DRUG CONJUGATES MARKET

4 PREMIUM INSIGHTS

  • 4.1 ANTIBODY DRUG CONJUGATES MARKET OVERVIEW
    • FIGURE 17 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
  • 4.2 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE AND COUNTRY (2022)
    • FIGURE 18 BREAST CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN ANTIBODY DRUG CONJUGATES MARKET IN 2022
  • 4.3 ANTIBODY DRUG CONJUGATES MARKET SHARE, BY PRODUCT, 2023 VS. 2028
    • FIGURE 19 KADCYLA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 ANTIBODY DRUG CONJUGATES: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH RATES FROM 2023 TO 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 ANTIBODY DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 ANTIBODY DRUG CONJUGATES MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of cancer
    • TABLE 5 GLOBAL INCREASE IN NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
      • 5.2.1.2 Increasing investments for ADC development
      • 5.2.1.3 Growing number of ADCs in clinical trials
    • TABLE 6 ASSET RANKING FOR LEADING ADC DEVELOPERS (2019 VS. 2023)
      • 5.2.1.4 Favorable regulatory support
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High manufacturing costs
      • 5.2.2.2 Side effects associated with ADCs
      • 5.2.2.3 High attrition rate in product development
    • TABLE 7 LIST OF DISCONTINUED ANTIBODY DRUG CONJUGATES (2020-2022)
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Adoption of combination therapies
      • 5.2.3.2 High growth in emerging economies
      • 5.2.3.3 Emergence of advanced ADCs
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technical complexities
  • 5.3 PIPELINE ANALYSIS
    • FIGURE 22 ANTIBODY DRUG CONJUGATES MARKET: CLINICAL TRIALS
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 23 ANTIBODY DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    • 5.5.1 ROLE IN ECOSYSTEM
  • 5.6 TECHNOLOGY ANALYSIS
    • TABLE 8 LEADING TECHNOLOGICAL ADVANCEMENTS FOR ADC GENERATIONS
  • 5.7 REGULATORY ASSESSMENT
    • 5.7.1 FDA REGULATIONS ON ANTIBODY DRUG CONJUGATES
      • 5.7.1.1 CLINICAL PHARMACOLOGY CONSIDERATIONS
    • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 14 ANTIBODY DRUG CONJUGATES MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.8.2 BARGAINING POWER OF SUPPLIERS
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 THREAT OF SUBSTITUTES
    • 5.8.5 THREAT OF NEW ENTRANTS
  • 5.9 PATENT ANALYSIS
    • 5.9.1 LIST OF MAJOR PATENTS
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 24 GROWING USE OF ACDS FOR ONCOLOGY AND OTHER CHRONIC DISEASES TO DRIVE MARKET
  • 5.11 PRICING ANALYSIS
    • TABLE 15 ANTIBODY DRUG CONJUGATES MARKET: PRICING ANALYSIS OF ADC PRODUCTS, BY REGION
    • TABLE 16 ANTIBODY DRUG CONJUGATES MARKET: PRICING ANALYSIS OF ADC PRODUCTS, BY KEY PLAYERS
  • 5.12 KEY CONFERENCES AND EVENTS
    • TABLE 17 ANTIBODY DRUG CONJUGATES MARKET: DETAILED LIST OF EVENTS AND CONFERENCES (2023-2024)
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 25 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND INFLUENCE ON BUYING PROCESS
    • FIGURE 26 KEY BUYING CRITERIA FOR ADC PRODUCTS AMONG END USERS

6 ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 18 ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 KADCYLA
    • 6.2.1 LAUNCH OF BIOSIMILARS TO DRIVE MARKET
    • TABLE 19 ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 ENHERTU
    • 6.3.1 RISING INCIDENCE OF BREAST CANCER TO PROPEL MARKET
    • TABLE 24 ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 25 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 28 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 ADCETRIS
    • 6.4.1 GROWING CASES OF HODGKIN LYMPHOMA TO DRIVE MARKET
    • TABLE 29 ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 30 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 PADCEV
    • 6.5.1 RISING INCIDENCE OF UROTHELIAL CANCER TO DRIVE MARKET
    • TABLE 34 ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 35 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.6 TRODELVY
    • 6.6.1 INCREASING GOVERNMENT APPROVALS FOR BREAST CANCER TO DRIVE MARKET
    • TABLE 39 ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.7 POLIVY
    • 6.7.1 RISING PREVALENCE OF NON-HODGKIN LYMPHOMA TO PROPEL MARKET
    • TABLE 44 ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.8 OTHER PRODUCTS
    • TABLE 49 ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 50 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)

7 ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE

  • 7.1 INTRODUCTION
    • TABLE 54 ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
  • 7.2 CLEAVABLE LINKERS
    • 7.2.1 HIGH COMPATIBILITY WITH BROAD RANGE OF DRUGS TO DRIVE MARKET
    • TABLE 55 ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 NON-CLEAVABLE LINKERS
    • 7.3.1 LOW TOXICITY LEVELS TO SUPPORT MARKET GROWTH
    • TABLE 60 ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)

8 ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE

  • 8.1 INTRODUCTION
    • TABLE 65 ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
  • 8.2 HER2
    • 8.2.1 RISING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
    • TABLE 66 ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 CD22
    • 8.3.1 INCREASING CASES OF B-CELL LYMPHOMAS TO DRIVE MARKET
    • TABLE 71 ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 72 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 CD30
    • 8.4.1 INCREASING CLINICAL TRIALS FOR PRODUCT LAUNCHES TO SUPPORT MARKET GROWTH
    • TABLE 76 ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 77 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 OTHER TARGET TYPES
    • TABLE 81 ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 82 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021-2028 (USD MILLION)

9 ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE

  • 9.1 INTRODUCTION
    • TABLE 86 ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
  • 9.2 MONOMETHYL AURISTATIN E
    • 9.2.1 CYTOTOXIC PAYLOAD FOR ADC DEVELOPMENT TO DRIVE MARKET
    • TABLE 87 ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 91 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 CALICHEAMICIN
    • 9.3.1 LAUNCH OF CALICHEAMICIN-BASED ADCS TO PROPEL MARKET
    • TABLE 92 ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 93 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 MAYTANSINOIDS
    • 9.4.1 INNOVATIVE PRODUCT PIPELINE TO SUPPORT MARKET GROWTH
    • TABLE 97 ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 98 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 OTHER PAYLOAD TYPES
    • TABLE 102 ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 103 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 104 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021-2028 (USD MILLION)

10 ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE

  • 10.1 INTRODUCTION
    • TABLE 107 ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
  • 10.2 BREAST CANCER
    • 10.2.1 RISING CASES OF INFLAMMATORY BREAST CANCER TO DRIVE MARKET
    • TABLE 108 PROJECTION OF BREAST CANCER RATES
    • TABLE 109 ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 110 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 113 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 BLOOD CANCER
    • 10.3.1 INCREASING FOCUS ON CLINICAL TRIALS FOR ADVANCED CONJUGATES TO PROPEL MARKET
    • TABLE 114 GLOBAL INCIDENCE OF BLOOD CANCER
    • TABLE 115 ESTIMATED NEW BLOOD CANCER CASES IN US (2023)
    • TABLE 116 ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 117 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 118 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 120 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 OTHER DISEASE TYPES
    • TABLE 121 ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 122 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 123 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 124 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 125 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)

11 ANTIBODY DRUG CONJUGATES MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 126 ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET SNAPSHOT
    • TABLE 127 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 128 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 129 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 132 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 Rising regulatory approvals for ADCs to drive market
    • TABLE 133 US: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 134 US: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 135 US: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 US: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 US: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 High R&D investments for novel ADCs to propel market
    • TABLE 138 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 139 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 140 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 141 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 142 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.2.3 NORTH AMERICA: RECESSION IMPACT
  • 11.3 EUROPE
    • TABLE 143 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 144 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 145 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 147 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 148 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Increasing collaborations among market players for cancer therapeutics to propel market
    • TABLE 149 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 150 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 152 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.3.2 FRANCE
      • 11.3.2.1 Growing demand for personalized therapeutics to drive market
    • TABLE 154 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 155 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 156 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 157 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Increasing cancer burden to support market growth
    • TABLE 159 UK: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 160 UK: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 161 UK: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 162 UK: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 163 UK: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Rising industrial collaborations for ADC production to drive market
    • TABLE 164 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 165 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 166 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 167 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Rising focus on drug discovery to support market growth
    • TABLE 169 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 170 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET, 2021-2028 (USD MILLION)
    • TABLE 173 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 174 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 175 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 176 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 177 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.3.7 EUROPE: RECESSION IMPACT
  • 11.4 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET SNAPSHOT
    • TABLE 179 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 180 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 181 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 182 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 183 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 184 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Rising initiatives for advanced therapies to drive market
    • TABLE 185 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 186 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 187 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 188 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 189 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Favorable regulatory support to propel market
    • TABLE 190 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 191 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 192 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 193 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 194 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Emergence of innovative biosimilars to drive market
    • TABLE 195 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 196 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 197 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 198 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 199 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 200 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 201 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 202 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 203 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 204 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 11.5 LATIN AMERICA
    • TABLE 205 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 206 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 207 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 208 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 209 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 210 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.5.1 BRAZIL
      • 11.5.1.1 Regulatory approvals for breast cancer therapeutics to drive market
    • TABLE 211 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 212 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 213 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 214 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET, 2021-2028 (USD MILLION)
    • TABLE 215 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.5.2 REST OF LATIN AMERICA
    • TABLE 216 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 217 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 218 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 219 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 220 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • 11.5.3 LATIN AMERICA: RECESSION IMPACT
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 RISING PRODUCT LAUNCHES FOR CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
    • TABLE 221 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 222 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
    • TABLE 223 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
    • TABLE 224 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
    • TABLE 225 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
  • 11.7 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 226 ANTIBODY DRUG CONJUGATES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE SHARE ANALYSIS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2019-2022)
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 227 ANTIBODY DRUG CONJUGATES MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
    • FIGURE 31 ANTIBODY DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (2022)
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
  • 12.6 COMPETITIVE BENCHMARKING OF 25 PLAYERS
    • 12.6.1 PRODUCT FOOTPRINT OF 11 COMPANIES
    • TABLE 228 ANTIBODY DRUG CONJUGATES MARKET: COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS
    • TABLE 229 ANTIBODY DRUG CONJUGATES MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
    • 12.6.2 REGIONAL FOOTPRINT OF 26 COMPANIES
    • TABLE 230 ANTIBODY DRUG CONJUGATES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
  • 12.7 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
    • FIGURE 32 ANTIBODY DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
    • 12.7.1 PROGRESSIVE COMPANIES
    • 12.7.2 STARTING BLOCKS
    • 12.7.3 RESPONSIVE COMPANIES
    • 12.7.4 DYNAMIC COMPANIES
  • 12.8 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
    • TABLE 231 ANTIBODY DRUG CONJUGATES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
    • TABLE 232 ANTIBODY DRUG CONJUGATES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 12.9 COMPETITIVE SCENARIO AND TRENDS
    • 12.9.1 PRODUCT LAUNCHES
    • TABLE 233 ANTIBODY DRUG CONJUGATES MARKET: PRODUCT LAUNCHES (JANUARY 2020-JUNE 2023)
    • 12.9.2 DEALS
    • TABLE 234 ANTIBODY DRUG CONJUGATES MARKET: DEALS (JANUARY 2020-JUNE 2023)

13 COMPANY PROFILES

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**

  • 13.1 KEY PLAYERS
    • 13.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 235 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 33 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 13.1.2 DAIICHI SANKYO COMPANY, LIMITED
    • TABLE 236 DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW
    • FIGURE 34 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)
    • 13.1.3 SEAGEN INC.
    • TABLE 237 SEAGEN INC.: BUSINESS OVERVIEW
    • FIGURE 35 SEAGEN INC.: COMPANY SNAPSHOT (2022)
    • 13.1.4 GILEAD SCIENCES, INC.
    • TABLE 238 GILEAD SCIENCES, INC.: BUSINESS OVERVIEW
    • FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • TABLE 239 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW
    • FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
    • 13.1.6 PFIZER INC.
    • TABLE 240 PFIZER INC.: BUSINESS OVERVIEW
    • FIGURE 38 PFIZER INC.: COMPANY SNAPSHOT (2022)
    • 13.1.7 ASTELLAS PHARMA INC.
    • TABLE 241 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
    • FIGURE 39 ASTELLAS PHARMA INC: COMPANY SNAPSHOT (2022)
    • 13.1.8 ASTRAZENECA
    • TABLE 242 ASTRAZENECA: BUSINESS OVERVIEW
    • FIGURE 40 ASTRAZENECA: COMPANY SNAPSHOT (2022)
    • 13.1.9 ADC THERAPEUTICS SA
    • TABLE 243 ADC THERAPEUTICS SA: BUSINESS OVERVIEW
    • FIGURE 41 ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2022)
    • 13.1.10 IMMUNOGEN, INC.
    • TABLE 244 IMMUNOGEN, INC.: BUSINESS OVERVIEW
    • FIGURE 42 IMMUNOGEN, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.11 ZYDUS GROUP
    • TABLE 245 ZYDUS GROUP: BUSINESS OVERVIEW
    • FIGURE 43 ZYDUS GROUP: COMPANY SNAPSHOT (2022)
  • 13.2 OTHER PLAYERS
    • 13.2.1 ABBVIE INC.
    • TABLE 246 ABBVIE INC.: BUSINESS OVERVIEW
    • 13.2.2 AMBRX
    • TABLE 247 AMBRX: BUSINESS OVERVIEW
    • 13.2.3 LEGOCHEM BIOSCIENCES, INC.
    • TABLE 248 LEGOCHEM BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • 13.2.4 BYONDIS
    • TABLE 249 BYONDIS: BUSINESS OVERVIEW
    • 13.2.5 PROFOUNDBIO
    • TABLE 250 PROFOUNDBIO: BUSINESS OVERVIEW
    • 13.2.6 REMEGEN
    • TABLE 251 REMEGEN: BUSINESS OVERVIEW
    • 13.2.7 SUTRO BIOPHARMA, INC.
    • TABLE 252 SUTRO BIOPHARMA, INC.: BUSINESS OVERVIEW
    • 13.2.8 LEPU BIOPHARMA CO., LTD.
    • TABLE 253 LEPU BIOPHARMA CO., LTD.: BUSINESS OVERVIEW
    • 13.2.9 ZYMEWORKS INC.
    • TABLE 254 ZYMEWORKS INC.: BUSINESS OVERVIEW
    • 13.2.10 MERSANA THERAPEUTICS
    • TABLE 255 MERSANA THERAPEUTICS: BUSINESS OVERVIEW
    • 13.2.11 DUALITY BIOLOGICS
    • TABLE 256 DUALITY BIOLOGICS: BUSINESS OVERVIEW
    • 13.2.12 LANOVA MEDICINES
    • TABLE 257 LANOVA MEDICINES: BUSINESS OVERVIEW
    • 13.2.13 EXELIXIS, INC.
    • TABLE 258 EXELIXIS, INC.: BUSINESS OVERVIEW
    • 13.2.14 BIONECURE THERAPEUTICS INC.
    • TABLE 259 BIONECURE THERAPEUTICS INC.: BUSINESS OVERVIEW
    • 13.2.15 TRIPARTITE THERAPEUTICS, INC.
    • TABLE 260 TRIPARTITE THERAPEUTICS, INC.: BUSINESS OVERVIEW
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS